Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands

Background: Coinciding with the relatively good and improving prognosis for patients with stage I-III breast cancer, late recurrences, new primary tumours and late side-effects of treatment may occur. We gained insight into prognosis for long-term breast cancer survivors. Patients and methods: Data on all 205 827 females aged 15-89 diagnosed with stage I-III breast cancer during 1989-2008 were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for every subsequent year from diagnosis up to 15 years. Results: For stage I, conditional 5-year relativ... Mehr ...

Verfasser: Heijnen, Maryska
van Steenbergen, LN
Voogd, AC
Tjan-Heijnen, VCG
Nijhuis, PH
Poortmans, PM
Coebergh, Jan Willem
van Spronsen, DJ
Dokumenttyp: Artikel
Erscheinungsdatum: 2014
Reihe/Periodikum: Heijnen , M , van Steenbergen , LN , Voogd , AC , Tjan-Heijnen , VCG , Nijhuis , PH , Poortmans , PM , Coebergh , J W & van Spronsen , DJ 2014 , ' Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands ' , Annals of Oncology , vol. 25 , no. 1 , pp. 64-68 . https://doi.org/10.1093/annonc/mdt424
Schlagwörter: /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being / SDG 3 - Good Health and Well-being
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-27618271
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://pure.eur.nl/en/publications/e7c05597-76c2-4f29-a68a-380c9f060afa

Background: Coinciding with the relatively good and improving prognosis for patients with stage I-III breast cancer, late recurrences, new primary tumours and late side-effects of treatment may occur. We gained insight into prognosis for long-term breast cancer survivors. Patients and methods: Data on all 205 827 females aged 15-89 diagnosed with stage I-III breast cancer during 1989-2008 were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for every subsequent year from diagnosis up to 15 years. Results: For stage I, conditional 5-year relative survival remained similar to 95% up to 15 years after diagnosis (a stable 5-year excess mortality rate of 5%). For stage II, excess mortality remained 10% for those aged 15-44 or 45-59 and 15% for those aged 60-74. For stage III, excess mortality decreased from 35% at diagnosis to 10% at 15 years for those aged 15-44 or 45-59, and from similar to 40% to 30% for those aged >= 60. Conclusions: Patients with stage I or II breast cancer had a (very) good long-term prognosis, albeit exhibiting a small but significant excess mortality at least up to 15 years after diagnosis. Improvements albeit from a lower level were mainly seen for patients who had been diagnosed with stage III disease. Caregivers can use this information to better inform (especially disease-free) cancer survivors about their actual prognosis.